Trevi Therapeutics, Inc. (TRVI)
13.51
0.00 (0.00%)
USD |
NASDAQ |
Nov 18, 16:00
13.54
+0.02
(+0.19%)
After-Hours: 20:00
Trevi Therapeutics Enterprise Value : 1.627B for Nov. 18, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 18, 2026 | 1.627B |
| November 17, 2026 | 1.627B |
| November 16, 2026 | 1.595B |
| November 13, 2026 | 1.647B |
| November 12, 2026 | 1.642B |
| November 11, 2026 | 1.813B |
| November 10, 2026 | 1.826B |
| November 09, 2026 | 1.883B |
| November 06, 2026 | 1.744B |
| November 05, 2026 | 1.527B |
| November 04, 2026 | 1.694B |
| November 03, 2026 | 1.677B |
| November 02, 2026 | 1.644B |
| October 30, 2026 | 1.634B |
| October 29, 2026 | 1.669B |
| October 28, 2026 | 1.628B |
| October 27, 2026 | 1.604B |
| October 26, 2026 | 1.484B |
| October 23, 2026 | 1.498B |
| October 22, 2026 | 1.545B |
| October 21, 2026 | 1.521B |
| October 20, 2026 | 1.530B |
| October 19, 2026 | 1.397B |
| October 16, 2026 | 1.394B |
| October 15, 2026 | 1.427B |
| Date | Value |
|---|---|
| October 14, 2026 | 1.420B |
| October 13, 2026 | 1.453B |
| October 12, 2026 | 1.544B |
| October 09, 2026 | 1.581B |
| October 08, 2026 | 1.529B |
| October 07, 2026 | 1.574B |
| October 06, 2026 | 1.580B |
| October 05, 2026 | 1.657B |
| October 02, 2026 | 1.684B |
| October 01, 2026 | 1.722B |
| September 30, 2026 | 1.742B |
| September 29, 2026 | 1.735B |
| September 28, 2026 | 1.733B |
| September 25, 2026 | 1.734B |
| September 24, 2026 | 1.772B |
| September 23, 2026 | 1.741B |
| September 22, 2026 | 1.852B |
| September 21, 2026 | 1.802B |
| September 18, 2026 | 1.811B |
| September 17, 2026 | 1.848B |
| September 16, 2026 | 1.819B |
| September 15, 2026 | 1.824B |
| September 14, 2026 | 1.945B |
| September 11, 2026 | 1.946B |
| September 10, 2026 | 1.948B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ANI Pharmaceuticals, Inc. | 1.808B |
| Corcept Therapeutics, Inc. | 7.052B |
| Veru, Inc. | 16.28M |
| Johnson & Johnson | 683.84B |
| Eli Lilly & Co. | 1.346T |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -21.45M |
| Total Expenses (Quarterly) | 21.45M |
| EPS Diluted (Quarterly) | -0.1343 |
| Earnings Yield | -2.93% |
| Normalized Earnings Yield | -2.929 |